Stemcell, 73002, AZD8055

AZD8055 is a potent, selective ATP-competitive inhibitor of mammalian target of rapamycin (mTOR), with an IC₅₀ value of 0.8 nM (Chresta et al.). It is very specific with ~1,000-fold selectivity for mTOR over all PI3K isoforms and exhibits no activity against a panel of 260 kinases at concentrations up to 10 µM (Chresta et al.).

CANCER RESEARCH

· Inhibits proliferation of A549 and H838 small-cell lung cancer cell lines in vitro, and inhibits tumor growth from a variety of human tumor xenografts in mice after oral administration (Chresta et al.).

· Inhibits cell proliferation, increases cell death and reduces migration in tamoxifen-resistant (TamR) and estrogen deprivation-resistant (MCF7-X) breast cancer cell lines (Jordan et al.).

· Induces apoptosis and inhibits proliferation in Hep-2, a human laryngeal cancer cell line (Zhao et al.).

· In combination with ABT-737, synergistically induces apoptosis in rhabdomyosarcoma (RMS) cells by suppressing expression of myeloid leukemia cell differentiation protein (MCL1; Preuss et al.).

· Inhibits proliferation and glycolysis, and induces apoptosis, in HeLa human cervical cancer cell line (Li et al.).